Overview

Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) Taking Salmeterol Xinafoate/Fluticasone Propionate Combination

Status:
Completed

Trial end date:
2012-06-01

Target enrollment:

Participant gender:

Summary

PH-797804 is an oral ant-inflammatory drug that may reduce the inflammation that is associated with COPD. PH-797804 will be dosed to patients with COPD to evaluate its potential safety and efficacy profile in COPD.

Phase:

Phase 2

Details

Lead Sponsor:

Pfizer

Treatments:

Fluticasone
Salmeterol Xinafoate